Cite
HARVARD Citation
Liao, W. et al. (2019). Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal of medical economics. pp. 344-349. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Liao, W. et al. (2019). Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal of medical economics. pp. 344-349. [Online].